Canada Markets closed
  • S&P/TSX

    20,206.41
    +106.60 (+0.53%)
     
  • S&P 500

    4,008.01
    -15.88 (-0.39%)
     
  • DOW

    32,223.42
    +26.76 (+0.08%)
     
  • CAD/USD

    0.7782
    -0.0002 (-0.0296%)
     
  • CRUDE OIL

    114.23
    +0.03 (+0.03%)
     
  • BTC-CAD

    38,529.36
    -1,701.34 (-4.23%)
     
  • CMC Crypto 200

    667.04
    +424.36 (+174.87%)
     
  • GOLD FUTURES

    1,825.00
    +11.00 (+0.61%)
     
  • RUSSELL 2000

    1,783.43
    -9.24 (-0.52%)
     
  • 10-Yr Bond

    2.8770
    -0.0580 (-1.98%)
     
  • NASDAQ futures

    12,264.50
    +19.75 (+0.16%)
     
  • VOLATILITY

    27.47
    -1.40 (-4.85%)
     
  • FTSE

    7,464.80
    +46.65 (+0.63%)
     
  • NIKKEI 225

    26,547.05
    +119.40 (+0.45%)
     
  • CAD/EUR

    0.7453
    -0.0001 (-0.01%)
     

MindMed to Present at H.C. Wainwright 2nd Annual Psychedelics Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, Dec. 1, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announced that MindMed's Chief Executive Officer, Robert Barrow, will participate in a panel and Company's management will participate in one-on-one investor meetings at the virtual H.C. Wainwright 2nd Annual Psychedelics Conference to be held on Monday, December 6, 2021.

Mindmed logo (PRNewsfoto/Mind Medicine, Inc. (Mindmed))
Mindmed logo (PRNewsfoto/Mind Medicine, Inc. (Mindmed))

Details on the panel discussion can be found below.

Topic: The Future of Mental Healthcare
Date: Monday, December 6, 2021
Time: 2:30 p.m. ET

A webcast of the company presentation will be available on-demand through the H.C. Wainwright conference portal beginning Monday, December 6, 2021 at 7:00 a.m. ET for those registered for the event.

About MindMed

MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed's approach to developing the next generation of psychedelic-inspired medicines and therapies.

MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.

Media Contact: mindmed@150bond.com
Investor Contact: bmackle@lifesciadvisors.com

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/mindmed-to-present-at-hc-wainwright-2nd-annual-psychedelics-conference-301434349.html

SOURCE Mind Medicine (MindMed) Inc.

Cision
Cision

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2021/01/c4773.html

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting